|Bid||0.0000 x 1000|
|Ask||0.0000 x 2900|
|Day's Range||2.6000 - 2.6600|
|52 Week Range||2.1400 - 25.9500|
|Beta (3Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Francescas Holdings (NASDAQ: FRAN ) shares ...
Shares of Can-Fite Biopharma Ltd. soared 18% in active premarket trading Tuesday, after the Israel-based drug development company announced a collaboration agreement with Israeli medical cannabis company Univo Pharmaceuticals Ltd. to develop cannabis components for the treatment of cancer, inflammatory, autoimmune and metabolic diseases. Trading volume in Can-Fite's spiked to 820,000 shares ahead of the open, compared with the full-day average of about 95,000 shares. Under terms of the agreement, Can-Fite and Univo will collaborate in the discovery, development and commercialization of medical cannabis-based therapeutics and the development and commercialization of cannabidiol (CBD) screening assays. As part of the deal, Can-Fite will pay $500,000 to Univo in two installments and is issuing 19.9 million of its ordinary shares, which represents 16.6% of the ordinary shares outstanding. Revenue from the collaboration will "generally be shared" based on each company's contribution. Can-Fite's stock has plunged 87.4% year to date through Monday, while the ETFMG Alternative Harvest ETF has gained 0.3% and the S&P 500 has rallied 18.8%.
It is widely recognized that the identification of specific receptors and pathways through which CBD operates is expected to greatly enhance the development of CBD-based pharmaceuticals. Can-Fite is uniquely positioned to contribute its deep pharmaceutical development expertise to the CBD market, based on findings published in peer reviewed scientific journals demonstrating that CBDs bind to the Gi protein-coupled A3 adenosine receptor (A3AR), which is over-expressed in pathological cells.
Two Israeli companies join forces to develop drugs to fight cancer and inflammatory, autoimmune and metabolic diseases.
PETACH TIKVA, Israel-- -- Upfront payments received from licensing deals in South Korea for Piclidenoson and Namodenoson with upfront and milestone payments of up to $10 million plus transfer pricing Preparatory work for an End of Phase II meeting with FDA to initiate Phase III study in liver cancer is ongoing Patient enrollment continues in two Phase III studies for Piclidenoson in the treatment ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that a supply of Namodenoson has been manufactured and is ready for use in the treatment of advanced liver cancer patients under compassionate use at the Rabin Medical Center in Israel. Compassionate use allows doctors and their patients the option of early access to investigational new drugs, under closely controlled and monitored circumstances, when a patient who is facing serious illness has exhausted all available treatment options.
Can-Fite BioPharma (NYSE: CANF) announced a new deal with Kyongbo Pharm to distribute the drug Piclidenoson for Psoriasis in South Korea, receiving $4 million payment upfront. For the exclusive distribution rights to sell Piclidenoson in South Korea, Kyongbo Pharm is making a total upfront payment of $750,000 to Can-Fite, with additional payments of up to $3,250,000 upon achievement of certain milestones. "We are very excited to sign this distribution agreement with Kyongbo, a highly prestigious company in South Korea and we believe that they are the right partner for us to penetrate the Korean market in the indication of psoriasis," stated Sari Fishman, VP business development of Can-Fite BioPharma.
Can-Fite BioPharma (NYSE: CANF ) 6-K shows the company filed an appeal with the Supreme Court of Israel of a decision related to the convening of a special shareholder meeting to replace directors. On ...
Can-Fite (CANF) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Can-Fite’s near term milestones include announcing top line results from its Phase II study of Namodenoson in the treatment of NAFLD/NASH. The Company currently has out-licensing agreements in several territories and has received approximately $17 million in upfront and milestone payments to date.
Phase III study protocol for Namodenoson in the treatment of advanced liver cancer patients is now being prepared and will be presented to FDA in an End of Phase II meeting
PETACH TIKVA, Israel-- -- Preparatory work for an end-of-Phase II FDA meeting to initiate a Phase III study in liver cancer is ongoing Top-line data from Phase II NASH study with Namodenoson expected in H2 2019 Patient enrollment continues in two Phase III studies for Piclidenoson in the treatment of rheumatoid arthritis and psoriasis Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline ...
During Thursday’s recap, I touched on why I think an excess of secondary offerings might be part of the reason for the faltering momentum. Four of the stocks I traded in the week, Can Fite Biopharma ADR (NYSE: CANF), Obalon Therapeutics Inc. (NASDAQ: OBLN), MYnd Analytics Inc. (NASDAQ: MYND) and OncoSec Medical Inc. (NASDAQ: ONCS) each announced a secondary offering. The net effect of these offerings is more share supply, less demand and a growing reticence amongst traders to buy into cheaper stocks like CANF and OBLN for fear of getting caught in a news halt and losing their shirts.
ICFL 2019 is focused on the clinical needs and best practices for diagnosing and treating fatty liver disease to address the challenges and long-term effects of this disease. ICFL 2019 will feature leading experts across the relevant fields to educate and foster knowledge exchange.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with certain institutional investors to receive gross proceeds of $6 million. In connection with the offering, the Company will issue 1,500,000 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $4.00 per ADS in a registered direct offering. Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase one ADS. The warrants will have an exercise price of $4.00 per ADS, will be immediately exercisable and will expire five and one-half years from the issuance date. The closing of the offering is expected to take place on or about May 22, 2019, subject to the satisfaction of customary closing conditions.
Shares of the biotech Can-Fite Biopharma Ltd (NASDAQ: CANF ) were skyrocketing Monday after an abstract describing data from the company's liver cancer study of the drug namodenoson was selected by the ...
PETACH TIKVA, Israel-- -- The International Liver Cancer Association Annual Conference has selected the Can-Fite abstract for presentation Phase III trial for Namodenoson in advanced liver cancer is now under preparation Namodenoson has both Fast Track status and Orphan Drug designation from the U.S. FDA Can-Fite BioPharma Ltd . , a biotechnology company with a pipeline of proprietary small molecule ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it is conducting preparatory work for a planned pivotal Phase III study of its drug candidate Namodenoson in the treatment of advanced liver cancer in patients as a first line and second line treatment. Namodenoson was found to increase overall survival in hepatocellular carcinoma (HCC) patients with Child Pugh B7, the largest subpopulation of the study, as compared to placebo, even though the trial did not meet its primary endpoint.
On the effective date, each ADS holder will be required to exchange every fifteen (15) ADSs then held for one (1) new ADS. The Bank of New York Mellon, the depositary bank, will arrange for the exchange of the current ADSs for the new ones.
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it has received a $1,000,000 payment from Chong Kun Dang Pharmaceuticals (CKD) (Korean Stock Exchange: 185750.KS) of South Korea. CKD has licensed the distribution rights to Namodenoson in South Korea for the treatment of liver cancer and non-alcoholic steatohepatitis (NASH) in a deal totaling $6,000,000 in upfront and milestone payments, plus a transfer price for delivering finished products to CKD.
PETACH TIKVA, Israel-- -- Acceptance for late breaking oral presentation underscores the oncology community’s interest in Namodenoson as a potential treatment for liver cancer Can-Fite now preparing for Phase III study of Namodenoson in patients with advanced liver cancer Child Pugh B 7 cirrhosis with Key Opinion Leader as Principal Investigator Can-Fite BioPharma Ltd . , a biotechnology company with ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with certain institutional investors to receive gross proceeds of approximately $3.2 million. In connection with the offering, the Company will issue 4,923,078 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $0.65 per ADS in a registered direct offering.
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S.
PETACH TIKVA, Israel-- -- Global distribution deals signed in Europe and China, including Can-Fite’s largest deal to date for up to $74.5 M Top-line data from Phase II Namodenoson trial in the treatment of liver cancer supports continuation into Phase III study Top-line Data from Phase II NASH Study with Namodenoson expected in H2 2019 Patient enrollment continues in two Phase III studies for Piclidenoson ...
The study did not achieve its primary end point of median overall survival in the whole population of 78 patients, however, superiority in median overall survival was found in the largest study subpopulation of 56 patients and in secondary end points including objective response in the whole population, strongly supporting the progression into Phase III.